This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
June 27, 2018
Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy
June 26, 2018
BioClin Therapeutics Appoints Scott Myers as Chairman to its Board of Directors
June 25, 2018
Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
June 22, 2018
Altimmune Restructures Financing Agreement
June 21, 2018
Nordic Nanovector Announces First Patient Dosed in Pivotal PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma Patients
June 20, 2018
Key Opinion Leaders highlight GS010 efficacy and patient benefits in discussion of findings from Reverse Phase III clincal trial
June 19, 2018
Targovax granted EU Patent for mutant-RAS neoantigen platform 2nd generation product TG02
June 18, 2018
Nexstim Plc SmartFocusTM TMS technology based therapy used across all university hospitals in Finland
June 17, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm
June 13, 2018
Nordic Nanovector Announces Archer-1 Trial of Betalutin® plus Rituximab in 2L Follicular Lymphoma Approved to Start in Norway